VALIC Company I Health Sciences (VCHSX)

23.77 -0.01  -0.04% Aug 7 USD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 23.77
Turnover Ratio 33.00%
1 Year Fund Level Flows -71.72M

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 2.24% 2.90% 65
3M 10.87% 11.00% 40
6M 9.90% 8.56% 36
YTD 11.34% 9.88% 34
1Y 26.17% 25.56% 40
3Y 15.24% 12.59% 19
5Y 9.02% 7.27% 35
10Y 19.93% 15.92% 5
15Y 14.92% 11.18% 3
20Y -- 9.02% --
As of Aug. 7, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.79% 0.79% 0.00%
Stock 97.68% 97.68% 0.00%
Bond 0.06% 0.06% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.86% 0.86% 0.00%
Other 0.60% 0.60% 0.00%
As of May 31, 2020

Region Exposure

Americas 86.33%
North America 86.33%
Latin America 0.00%
Greater Europe 9.81%
United Kingdom 2.13%
Europe Developed 7.65%
Europe Emerging 0.00%
Africa/Middle East 0.02%
Greater Asia 3.86%
Japan 2.22%
Australasia 0.00%
Asia Developed 0.05%
Asia Emerging 1.59%
Market Classification
% Developed Markets 98.41%
% Emerging Markets 1.59%
As of May 31, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.56%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.14%
Healthcare 99.04%
Industrials 0.27%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of May 31, 2020

Stock Market Capitalization

Giant 27.10%
Large 35.63%
Medium 27.20%
Small 9.23%
Micro 0.85%
As of May 31, 2020

Stock Style Exposure

Large Cap Value 9.25%
Large Cap Blend 37.95%
Large Cap Growth 18.28%
Mid Cap Value 0.30%
Mid Cap Blend 3.63%
Mid Cap Growth 23.62%
Small Cap Value 0.75%
Small Cap Blend 1.25%
Small Cap Growth 4.97%
As of May 31, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
UNH UnitedHealth Group Inc 5.56% 317.03 +0.95%
VRTX Vertex Pharmaceuticals Inc 4.32% 272.99 -0.13%
TMO Thermo Fisher Scientific Inc 3.53% 414.33 -0.34%
ISRG Intuitive Surgical Inc 3.43% 685.85 -0.78%
BDX Becton, Dickinson and Co 2.98% 256.41 -1.23%
REGN Regeneron Pharmaceuticals Inc 2.18% 620.21 -0.16%
AMGN Amgen Inc 2.11% 240.69 -0.36%
HUM Humana Inc 2.08% 417.94 +2.53%
CNC Centene Corp 2.06% 64.28 +0.88%
LLY Eli Lilly and Co 2.06% 152.93 +0.03%
As of May 31, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks long-term capital growth. The fund normally invests at least 80% of its net assets in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund may invest up to 35% of its total assets in foreign stocks, which include non-dollar denominated securities traded outside the U.S.
General
Security Type Mutual Fund
Oldest Share Symbol VCHSX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name VALIC
Benchmark Index
S&P 500 Sec/Health Care TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Ziad Bakri 4.34 yrs

Net Fund Flows

1M -10.96M
3M -14.98M
6M -20.61M
YTD -31.69M
1Y -71.72M
3Y -174.19M
5Y -352.90M
10Y -153.78M
As of July 31, 2020

Risk Info

Beta (5Y) 1.002
Historical Sharpe Ratio (10Y) 1.174
Historical Sortino (All) 0.823
Daily Value at Risk (VaR) 1% (All) 3.77%
Monthly Value at Risk (VaR) 1% (All) 17.24%

Fundamentals

Dividend Yield TTM (8-7-20) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 27.75
Weighted Average Price to Sales Ratio 2.592
Weighted Average Price to Book Ratio 5.177
Weighted Median ROE 7.62%
Weighted Median ROA -1.14%
Forecasted Dividend Yield 0.77%
Forecasted PE Ratio 21.63
Forecasted Price to Sales Ratio 2.268
Forecasted Price to Book Ratio 4.646
Number of Holdings 235
As of May 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 11.18%
Forecasted Book Value Growth 10.54%
Forecasted Cash Flow Growth 11.66%
Forecasted Earnings Growth 21.77%
Forecasted Revenue Growth 12.81%
As of May 31, 2020

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 0.00 USD
Minimum Subsequent Investment 0.00 USD
Fees
Actual 12B-1 Fee --
Actual Management Fee 0.98%
Administration Fee 0.06%
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 11/1/2000
Termination Date
Last Annual Report Date 5/31/2019
Last Prospectus Date 10/1/2019
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product Yes
Available for Retirement Plan Yes
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.